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Thrombin enhances the adhesion and migration of human colon
adenocarcinoma cells via increased fl3-integrin expression on the tumour
cell surface and their inhibition by the snake venom peptide, rhodostomin
H-S Chiang', R-S Yang2 and T-F Huang'
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Summary The interactions between tumour cells and the microvasculature, including the adhesion of tumour
cells to endothelium and extracellular matrix (ECM) as well as their migratory ability, are prerequisites for
metastasis to occur. In this study we showed that thrombin is capable of enhancing in vitro tumour cell
metastatic potential in terms of adhesive properties and migratory response. Following exposure to subclotting
concentrations of thrombin, SW-480 human colon adenocarcinoma cells exhibited increased adhesion to both
the endothelium and ECM component (i.e. fibronectin). Likewise, the pretreatment of thrombin enhanced the
migratory ability of SW-480 cells. The enhanced adhesion was significantly inhibited by complexing of
thrombin with its inhibitor hirudin, or by serine proteinase inhibition with 3,4-DCI, but was unaffected by
pretreatment of tumour cells with actinomycin D or cycloheximide. The effect of thrombin resulted in an up-
regulated cell-surface expression of 13 integrins, a group of receptors mediating interactions between tumour
cells and endothelial cells, and between tumour cells and ECM. Antibodies against (3 integrins effectively
blocked both the enhanced adhesion and migration. This thrombin-mediated up-regulation of f3 integrins
involved the activation of protein kinase C (PKC) as thrombin-enhanced adhesion was diminished by PKC
inhibition. Rhodostomin, an Arg-Gly-Asp-containing antiplatelet snake venom peptide that antagonises the
binding of ECM toward 13 integrins on SW-480 cells, was about 600 and 500 times, more potent than RGDS
in inhibiting thrombin-enhanced adhesion and migration respectively. Our data suggest that PKC inhibitors as
well as rhodostomin may serve as inhibitory agents in the prevention of thrombin-enhanced metastasis.
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The metastatic cascade of tumour cells is a sequence of
complex events characterised by their growth at the primary
site, invasion of surrounding tissues, penetration into
vasculature and transport to distant sites and implantation
and formation of secondary lesions. The haematogenous
phase of metastasis involved a variety of cell-cell and cell-
ECM interactions. Tumour cell interaction with endothelium
and ECM, a process believed to determine organ-specific
metastasis, is mediated by a wide spectrum of cell-surface
adhesion molecules, including integrin receptors (Honn et al.,
1992a, b). There is evidence that systemic or local activation
of blood coagulation promotes metastasis, whereas inhibition
of the blood clotting cascade favours the host and diminishes
metastatic spread (Honn and Sloane, 1984). However, the
exact nature of this association and its potential practical
significance are not yet completely understood.
It has been known for over a century that most cancer
patients manifest laboratory signs of hypercoagulability and
some develop thromboembolic disease (Rickles et al., 1992).
Clinical trials of anticoagulants or fibrinolytic agents have
exhibited improvements in the incidence of tumour regression
and in overall survival (Zacharski et al., 1992a). Therefore,
the mainstream of clinical and basic investigators has focused
on the role of interactions between tumour cells and the host
coagulation system. In certain tumour types, in situ fibrin, the
final product of blood coagulation, is present predominantly
at the host-tumour interface in abundant amounts
(Zacharski et al., 1992b). Fibrin deposited at the primary
site constitutes a component of tumour stroma, which
protects tumour cells against cells of the host defence system
and facilitates tumour angiogenesis (Zacharski et al., 1992b;
Costantini and Zacharski, 1993). Thrombin, a pluripotent
bioregulatory serine proteinase, was reported to enhance the
metastatic phenotype of mammary tumour cells by increasing
their proliferative response (Medrano et al., 1987) and was
also found to be a potent mitogen for tumour cells (Bruhn
and Zurborn, 1983). In fact, in our previous study (Chiang et
al., 1994a), thrombin was shown to mediate SW-480 tumour
cell-induced platelet aggregation (TCIPA), which might be
important for successful metastasis to occur (Cavanaugh et
al., 1988).
In recent years, purified antiplatelet components from
snake venoms, including trigramin-like antiplatelet peptides
(Huang et al., 1987a, 1991a, b; Rucinski et al., 1990; Shebuski
et al., 1989) have been widely studied. Trigramin, an Arg-
Gly-Asp (RGD)-containing peptide purified from venom of
the snake Trimeresurus gramineus, is a specific antagonist of
platelet membrane glycoprotein IIb/IIIa (Huang et al., 1987a,
1989). Rhodostomin, an RGD-containing peptide purified
from the venom of the Malayan pit viper, Agkistrodon
rhodostoma, likewise directly impairs fibrinogen interaction
with its specific receptor associated with glycoprotein IIb/IIIa
(Huang et al., 1987b, 1990). These trigramin-like peptides all
contain an RGD epitope, are rich in cysteine and bind with
high affinity to the surface of platelets.
The present study documents the effect of thrombin
treatment with SW-480 human colon adenocarcinoma cells
on regulation of their surface integrin expression, cell
adhesive and migratory properties. Rhodostomin was found
to strongly inhibit thrombin-enhanced tumour cell adhesion
and migration. We also compared the effect of MAbs and
synthetic peptide RGDS.
Materials and methods
Materials
SW-480 human colon adenocarcinoma cells were provided by
the Department of Bacteriology, College of Medicine,
National Taiwan University. Agkistrodon rhodostoma (or
Calloselasma rhodostoma) venom was purchased from
Latoxan (France) and stored at -20°C. Rhodostomin was
purified from venom of A. rhodostoma as previously
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1995described (Huang et al., 1990). Synthetic peptide RGDS was
purchased from Peninsula Laboratories, CA, USA. Human
thrombin (3000 NIH units mg-'), hirudin (grade IV from
leeches), 3,4-dichloroisocoumarin (3,4-DCI), cycloheximide,
actinomycin D and fibronectin (from bovine plasma) were
obtained from Sigma, St Louis, MO, USA. Thrombin-
hirudin or thrombin-serine protease inhibitor complex was
formed by incubation for 30 min at 37°C of equimolar
concentrations of human thrombin with either inhibitor
(heparin, 5 U ml-'; 3,4-DCI, 0.1 mM). The thrombin-
hirudin complex had no fibrinogen clotting activity.
Staurosporine was obtained from Biomol Research Labora-
tories, PA, USA. Calphostin C (isolated from Cladosporium
cladosporioides) was from Research Biochemicals Interna-
tional, MA, USA. Goat anti-mouse IgG-FITC was from
Boehringer, Mannheim, Germany. Monoclonal antibodies
(MAbs) 7E3 and 10E5 against platelet GPIIb/IIIa complex
were kindly supplied by Dr B Coller (State University ofNew
York, Stony Brook, USA). The specificity of these antibodies
for human platelet IIbf3 was reported previously (Grossi et
al., 1988; Chopra et al., 1988). MAb against f,3 integrin
(MAB1977) was obtained from Chemicon, CA, USA
MCA698 (anti-X5fi) and MCA699 (anti-C461,) were pur-
chased from Serotec, Bicester, UK.
Methods
Cell culture SW-480 human colon adenocarcinoma cells
were grown in 95% air-5% carbon dioxide in Dulbecco's
modified Eagle medium (DMEM) tissue culture medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS), 2 mM glutamine, penicillin (100 U ml-') and strepto-
mycin (100 pg ml-'). Cells were passed and harvested for
experiments before reaching confluence. Human umbilical
vein endothelial cells (HUVECs) were prepared as described
by Jaffe et al, (1973). Umbilical cord veins were cannulated
and flushed with cord buffer to remove blood and then filled
with 0.1% collagenase solution (type I, Sigma) for 15-
20 min at 37°C. Detached cells were recovered by flushing
with M199 and collected by centrifugation at 1000 r.p.m. for
5 min. The cells were then suspended in M199 containing
20% FCS, penicillin (100 U ml-') and streptomycin
(100 pg ml-') before seeding. After 18-24 h incubation the
medium was removed, the cells washed gently before fresh
medium was added. Human microvascular endothelial cells
(HMVECs) were kindly provided by Dr MW Swaim (Duke
University Medical Center, NC, USA) and grown in
DMEM-F12 medium containing 20% FCS. HMVEC line
was used within sixth passages. Both endothelial cells were
identified as positively immunofluorescent staining for von
Willebrand factor antigen.
Adhesion studies SW-480 cells were harvested with 0.25 mM
EDTA (5 min, 37°C). EDTA has been demonstrated to
dissociate the platelet IIb/IIIa complex (Fitzgerald and
Phillips, 1985). Therefore, tumour cells were washed free of
serum proteins with Hanks' balanced salt solution (HBSS,
pH 7.25) containing 2 mM Ca2" and 2 mM Mg2". 2',7'-Bis-(2-
carboxyethyl)-5(and-6)-carboxyfluorescein acetoxymethyl
(BCECF-AM, Molecular Probes, OR, USA) has been used
in fluorescence-based viability assessment in adherent cell
cultures (Vaporciyan et al., 1993). In our study, cells (5 x 104)
were incubated with fluorescent dye (2 pg ml-') in HBSS for
30 min at 37°C. Following incubation, cells were washed
once in phosphate-buffered saline (PBS), and finally
resuspended in HBSS containing 2 mM Ca2" and 2 mM
Mg2+. Monolayers of endothelial cells, grown to confluence
in Costar 48-well plates, were used for adhesion studies.
Aliquots of fibronectin (1.5 pg per well) dissolved in PBS
were placed in Costar 96-well plates. The coated wells were
kept in a laminar flow hood to air dry overnight, and washed
with PBS immediately before adhesion assay. Cells were
incubated with buffer or 0.5 U ml-' thrombin for 30 min,
followed by washing and then addition of buffer, antibodies,
RGDS or rhodostomin and incubated for 30 min before
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adhesion assay. In some experiments, cells were treated with
various concentrations of cycloheximide, actinomycin D,
staurosporine or calphostin C for 20 min at room
temperature before incubation with thrombin. Pretreated
cells were then washed once with PBS and used immediately
in adhesion assays. Treated or untreated cells (2.5 x 104) were
added to each well and incubated (60 min) at 370C. Each
condition was run in quadruplicate and all experiments were
repeated at least four times with similar results. Non-
adherent cells were removed by aspiration and plates were
read with a CytoFluor 2300 fluorescence plate reader
(Millipore, Bedford, MA, USA).
Cell migration assays Cell migration assays were carried out
in millicell-PCF inserts (Millipore) by using standard 24-well
tissue culture plates (Costar, USA). Briefly, SW-480 cells
were harvested and incubated with BCECF-AM as previously
described (Chiang et al., 1994b). The fluorescence-loaded cells
were then resuspended in DMEM without serum and
preincubated with buffer or thrombin (0.5 U ml-') for
30 min at 370C, followed by washing and addition of either
buffer or 3.5 pg ml-' rhodostomin before migration assays.
They were added (3 x 105 cells ml-') to the upper compart-
ment of a millicell-PCF insert and the lower compartment
was filled with medium containing a chemoattractant:
fibronectin (30 pg ml-') and control medium (serum-free
DMEM containing 0.1% bovine serum albumin). The two
compartments of the millicell-PCF inserts were separated by
a polycarbonate filter (12 pm pore size) precoated with
gelatin (5 pg ml-1, Sigma). SW-480 cells were allowed to
migrate for 14 h at 37°C in a humidified atmosphere
containing 5% carbon dioxide. Cells on the upper side of
the filter were removed mechanically, and the adherent cells
on the lower side of the filter were read with a CytoFluor
2300 fluorescence plate reader (Millipore Corp.) as described
in cell adhesion assays.
Flow cytometric analysis Flow cytometric studies were
performed to quantify surface expression of integrins
(Chiang et al., 1994b). SW-480 cells were detached (using
0.5 mM EDTA), washed and then stimulated with 0.5 U ml-'
thrombin at 37°C for 30 min in 500 p1 of PBS containing 106
cells per sample. Following washing the cells were fixed with
2.7% paraformaldehyde for 10 min, blocked with normal
goat serum (1:2) for 25 min, and labelled with MAbs
(20 pg ml-') for 1 h. After washing cells were relabelled
with goat anti-mouse IgG-FITC. FITC signals were detected
and digitised in logarithmic configuration and the data
collected on a EPICS computer system. Data were collected
in 256-channel resolution and 10 000 cells were counted
per experimental group. Fluorescence intensity was directly
proportional to the fluorescein label present on the
tumour cell surface. All experiments were repeated at least
four times.
Results
Effect of thrombin on SW-480 tumour cell adhesion to
human endothelial cells
In this study we showed that SW-480 human colon
adenocarcinoma cells respond to human thrombin by
increased adhesion to human endothelial cell monolayers,
HMVEC and HUVEC. We used different concentrations of
thrombin, ranging from 0.01 to 5 U ml-' with incubation
time of 30 min. Figure la shows that stimulation of SW-480
cells with various concentrations of thrombin exhibited bell-
shaped dose-response curves in increasing adhesion to
endothelial cells (ECs) with a peak at 0.5 U ml-'. The
maximal effects for HUVEC and HMVEC were approxi-
mately 3.5- and 2.3-fold increases respectively in the number
of adherent cells. Both increments were significant effects
(P<0.001). A concentration of thrombin as low as
0.01 U ml-' enhanced adhesion, whereas higher concentra-
tions (i.e. 5 U ml-') were ineffective.Rhodostomin inhibits thrombin-enhanced adhesion and migration
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Effect of thrombin on SW-480 tumour cell adhesion to
fibronectin
Fibronectin (FN), which is found in the fibro-connective
tissue stoma, was also used as a substratum for studies of
SW-480 cell-adhesion. Thrombin treatment resulted in a
maximal response of approximately 2.5-fold increase in the
number of adherent cells. The dose-response curve was also
bell-shaped, with the maximal effect at 0.5 U ml-' (Figure
la). However, similar to the results from adhesion to ECs,
subclotting concentrations of thrombin (i.e., 0.01 U ml-')
also enhanced adhesion whereas higher concentrations (i.e.,
5 U ml-') did not. Incubation of SW-480 cells with thrombin
for different time periods also revealed a bell-shaped pattern
(Figure lb). A slight increase was observed 5 min after
pretreatment with thrombin and the optimal response
occurred when tumour cells were stimulated with thrombin
for a period ranging between 30 min and 4 h. Prolonged
incubation of tumour cells (8-24 h) with thrombin resulted
in a decrease in tumour cell adhesion.
When thrombin was mixed with hirudin, a specific
thrombin inhibitor, a profound inhibition was found
compared with the buffer control (Figure 2). This suggests
that an intact thrombin molecule is apparently required to
enhance SW-480 cell adhesion. In addition, an irreversible
serine protease inhibitor, 3,4-DCI, was observed to
completely block thrombin-enhanced adhesion of SW-480
cells to FN, further suggesting that the active site serine
residue is required for the enhancing effect of thrombin.
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Figure 1 Dose- and time effect ofthrombin in enhancing tumour
cell adhesion. (a) SW-480 cells were pretreated with various
concentrations of thrombin for 30min at 37°C, and tested for
adhesion to human endothelial cells (HUVEC, A; HMVEC, 0)
and fibronectin (I) after 60min. The adherent cells were
evaluated as described in Materials and methods. (b) SW-480
cells were preincubated with thrombin (0.5Uml-1) at 37°C for
various indicated time intervals and adhesion to fibronectin was
assayed. Data are presented as mean+ s.e.m. (n =4). *P<0.05,
**P<0.01, ***P<0.001.
However, thrombin-enhanced adhesion was not affected by
pretreatment of cells with either cycloheximide or actinomy-
cin D, the inhibitors of protein synthesis and RNA synthesis
respectively (Figure 2).
Effect ofprotein kinase C inhibitors on thrombin-enhanced
SW-480 tumour cell adhesion tofibronectin
It is well recognised that protein kinase C (PKC) activation,
an important part of signal transduction, is involved in
growth regulation of many tumours and in metastasis (Liu et
al., 1992). In our previous study, we found that PKC
activation resulted in up-regulation of integrin on SW-480
cells and thus increased their adhesion (Chiang et al., 1994b).
Thrombin was reported to either activate or down-regulate
PKC, depending on the cell type studied (Gomez et al., 1988).
Therefore we used two PKC inhibitors to examine whether
PKC is implicated in thrombin-enhanced SW-480 tumour cell
adhesion. Pretreatment of SW-480 cells with either staur-
osporine (Figure 3a), a potent but relatively less selective
PKC inhibitor, or calphostin C (Figure 3b), a selective PKC
inhibitor, blocked thrombin-enhanced adhesion to FN in a
dose-dependent manner. Maximal inhibition was approxi-
mately 80% of basal (i.e. unstimulated) adhesion by either
inhibitor, suggesting that PKC activation is a key event in
thrombin-enhanced adhesion. However, basal adhesion was
not significantly affected by PKC inhibition.
Effect ofrhodostomin and an MAb against 33 integrin on
thrombin-enhanced SW-480 tumour cell adhesion
Tumour cell adhesion to ECs and ECM is mediated by cell-
surface adhesion molecules, including the integrin receptors.
The f3 integrins (i.e. aIIbl3 and 4v33) were detected in several
tumour cells (Chopra et al., 1988; McGregor et al., 1989) that
have been implicated in tumour cell-platelet (Chopra et al.,
1988), tumour cell-ECM and tumour cell-ECs (Grossi et
al., 1989) interactions. Therefore we investigated the possible
role of f3 integrin in thrombin-enhanced SW-480 cell
adhesion. Stimulation of SW-480 cells with 0.5 U ml-'
thrombin (30 min at 37°C) was followed by an incubation
with 1OE5 (30 gg ml-'), an MAb that does not cross-react
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Figure 2 Effect of hirudin as well as inhibitors of serine
proteinase, protein synthesis and RNA synthesis on thrombin-
enhanced SW-480 tumour cell adhesion to fibronectin. SW-480
cells were stimulated with optimal dose of human thrombin
(0.5Uml-'), thrombin-hirudin or thrombin-3,4-DCI complex
(each complex contained 0.5Uml-1 thrombin) for 30min at
37°C, and the adhesion was tested after 60min. In other
experiments SW-480 cells were incubated with various concentra-
tions of cycloheximide or actinomycin D for 20min at room
temperature before the addition of thrombin (0.5Uml-1) for
30min at 37°C. Data are presented as mean+s.e.m. (n=4).
*P<0.05, **P<0.01, ***P<0.001, compared with thrombin-
enhanced adhesion.
A^^with the vitronectin (4v/33) or fibronectin (@5/1) receptors,
resulting in marked inhibition in thrombin-enhanced adhe-
sion to both human ECs and FN (Figure 4a-c respectively).
However, in all cases, adhesion was reduced to basal levels by
pretreatment with 7E3 (30 ,ug ml-'), an MAb that recognises
an antigenic determinant on the P subunit of GpIIb/IIIa (i.e.
GpIIIa) (Chopra et al., 1988), suggesting that /l3 integrins
played an important role in thrombin-enhanced SW-480 cell
adhesion. Rhodostomin, an RGD-containing peptide, po-
tently blocked the SW-480 cell adhesion response to
thrombin at a concentration of 2.3 Mg ml-' (0.3 juM). The
synthetic peptide RGDS had a similar inhibition with the
maximal effect at 75 Mg ml-' (176 gM). On a molar basis,
therefore, rhodostomin is about 600 times more potent than
RGDS in inhibiting thrombin-enhanced adhesion.
Effect of rhodostomin on thrombin-enhanced SW-480 tumour
cell migration
The migratory activity of SW-480 cells was assayed in
millicell-PCF inserts by using 24-well plates as described in
Materials and methods. As shown in Figure 5, SW-480
human colon adenocarcinoma cells migrated positively to
FN, vitronectin (VN) and laminin (LM) containing compart-
ments. Pretreatment of SW-480 cells with thrombin
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(0.5 U ml-1 for 30 min at 370C) significantly enhanced
migration to VN and FN, whereas it did not enhance SW-
480 tumour cell migration to LM or control medium
containing bovine serum albumin. Cells in the presence of
rhodostomin (2.8 jug ml-') showed significant reduced
activity in both control- and thrombin-enhanced migration
(Figure 5), which were reduced approximately to the level of
that in control medium. Likewise, the synthetic peptide
RGDS at 80 gg ml-' had a similar inhibitory effect. On a
molar basis, rhodostomin is about 500 times more potent
than RGDS at inhibiting control- and thrombin-enhanced
migration. These enhanced migrations were also reduced to
basal levels by pretreatment with 30 jg ml-' 7E3 (data not
shown).
Effect of thrombin on integrin expression in SW-480 cells
Since MAb 7E3 completely blocked thrombin-enhanced
adhesion on both ECs and FN, we examined the surface
expression of P3 integrins, the binding epitopes for 7E3, on
SW-480 cells following stimulation with thrombin. Pretreat-
ment of SW-480 cells with 0.5 U ml-' thrombin (30 min at
370C) was followed by primary labelling with 7E3 and
subsequently incubation with anti-mouse IgG-FITC. Fluor-
escence intensity was analysed by flow cytometry as described
Control 0.05 0.5 2 .r' E 0.05 0.5 2 5
Calphostin C (M) 2 D Calphostin C (m) +
Cs 0.5 U ml thrombin
Figure 3 Effects of (a) staurosporine, and (b) calphostin C, on
basal and thrombin-enhanced SW-480 tumour cell adhesion. SW-
480 cells were preincubated with various concentrations of
staurosporine or calphostin C for 20min at room temperature,
then stimulated with thrombin (0.5Uml-) for 30min at 37°C.
Finally, these cells were washed once, resuspended and allowed to
adhere to fibronectin-coated plates for 60min at 370C. TPA
(0.1,IM, 37°C for 5min) was used as a positive control for PKC
activation, as we previously reported (Chiang et al., 1994b). Data
are presented as mean+s.e.m. (n =4-5). For (a), *P<0.05,
**P<0.01, ***P<0.001; for (b), ##P<0.01, ###P<0.001. Both
symbols are compared with respective thrombin-enhanced
adhesion.
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Figure 4 Inhibition of thrombin-enhanced SW-480 cell adhesion
by MAbs, rhodostomin and RGDS. SW-480 cells were stimulated
with thrombin (0.5 Uml-1) at 37°C for 30min, then washed once
and incubated with IOE5, 7E3 (both at 30pgml-'), rhodostomin
(2.3gml-F') or RGDS (75jugml-') for 30min at room
temperature. Finally, these cells were allowed to adhere to (a)
HUVEC, (b) HMVEC and (c) fibronectin (FN)-coated plates for
60min at 37°C. Data are presented as mean+s.e.m. (n=4-5).Rhodostomin inhibits thrombin-enhanced adhesion and migration
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in Materials and methods. As shown in Figure 6a and b,
thrombin-stimulated cells exhibited an increase in the number
of cells positively stained for P3 integrins and an enhanced
fluorescence. Figure 6c shows the quantitative results of P3
integrin expression on SW-480 cells stimulated by thrombin,
indicating that both mean fluorescence intensity and the
mean number of positively staining cells were significantly
increased. However, cells probed first with MAbs MAB1977
(anti-PlI integrin), MCA698 (anti-x5#,1) or MCA699 (anti-CX60,)
did not show a significant increase in fluorescence intensity in
response to thrombin pretreatment (data not shown).
Discussion
Rhodostomin, an RGD-containing disintegrin, has been
demonstrated to directly impair fibrinogen interaction with
its specific receptor associated with GP IIb/IIIa (Huang et al.,
1987b, 1990). We previously showed that rhodostomin is
about 18 000 times more potent that the synthetic peptide
GRGDS in inhibiting SW-480 TCIPA, a thrombin-dependent
reaction owing to SW-480 tissue factor activity expression, by
virtue of its antiplatelet activity (Chiang et al., 1994a). We
also reported that rhodostomin binds via its RGD sequence
to multiple integrin receptors (i.e. aIIbMP3, c,#39, cL5f,) expressed
on the SW-480 cell surface, and thereby blocks the adhesion
of SW-480 cells to ECM (Chiang et al., 1994b). In the present
study, rhodostomin was further shown to significantly block
thrombin-enhanced adhesion and migration of SW-480 cells,
the two major events determining the tumour metastasis
potential. Rhodostomin was about 600 and 500 times more
potent than RGDS in inhibiting thrombin-enhanced SW-480
cell adhesion and migration respectively.
Activation of blood coagulation, a common feature in
cancer patients, leads to the generation of thrombin. The
biological effect ofthrombin, as well as its role in TCIPA and
fibrin formation may favour the metastatic spread of cancer
by promoting cell migration, mediating tumour cell adhesion,
stimulating autocrine growth factor secretion or inducing
neovascularisation (Costantini and Zacharski, 1993; Wojtu-
kiewicz et al., 1992; Zacharski et al., 1990). In the present
study, thrombin was found to enhance SW-480 tumour cell
adhesion and migration with the optimal concentration of
0.5 U ml-'. According to a previous study, during clotting of
whole blood or plasma, only approximately 15 U ml-'
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Figure 5 Effect of thrombin on SW-480 cell migration and its
inhibition by rhodostomin and RGDS. Cell migration assays were
carried out in millicell-PCF inserts by using a standard 24-well
tissue culture plates as described in Materials and methods. The
lower compartment was filled with media containing fibronectin
(FN), vitronectin (VN) and laminin (LM). Thrombin-treated SW-
480 cells (3 x 105 cells ml-) were added to the upper
compartment of a millicell-PCF insert in the absence or in the
presence of rhodostomin (2.8pgml-1) or RGDS (80ugml-1).
Migration assays were performed for 14h at 37°C in a humidified
atmosphere containing 5% carbon dioxide. Data are presented as
mean+s.e.m. (n=4). *P<0.05, **P<0.01, ***P<0.001.
_--
Thrombin
100
75 -0
0
05 0. 25 CL
.25
n
Figure 6 Quantification by flow cytometry of thrombin-
enhanced surface expression of fi3 integrins on SW-480 cells.
SW-480 cells were pretreated with thrombin (0.5Uml- 1, 37°C for
30min) and then labelled with MAb 7E3 (15pgml-', room
temperature for 60min), followed by incubation with anti-mouse
IgG-FITC. Mean fluorescence intensity was quantified on an
EPICS computer system. Thrombin-treated cells (b) showed an
increase in fluorescence intensity when compared with cells
incubated with buffer (a). (c) Thrombin-treated SW-480 cells
demonstrated increases in both the mean fluorescence intensity
(El) and the mean number of positively staining cells (-) when
compared with control cells incubated with buffer only. Data are
presented as mean+s.e.m. (n=4). *P<0.05, **P<0.01.
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thrombin is ever measurable, despite more than 80%
consumption of prothrombin (Fenton, 1988). Therefore,
tumour cells require only low subclotting concentrations of
thrombin to elicit their optimal adhesion response. One
possibility leading to prolonged tumour cell exposure to low
thrombin concentrations in the microcirculation is the
interactions of tumour cells with platelets and blood plasma
components, resulting in the formation of microthrombi
containing tumour emboli. This unique clot structure may
serve as a thrombin reservoir and protects thrombin from
neutralisation by serine protease inhibitors (Fenton, 1988).
Thus, tumour cells entrapped in the fibrin clot may be under
a constant stimulation by thrombin and become more
predisposed to successful metastasis.
The optimal effectiveness of low concentrations of
thrombin for enhanced adhesion and migration suggests a
thrombin-receptor-mediated mode of action. At present,
there are two major thrombin receptors reported. Glycopro-
tein lb (GP Tb), the predominant thrombin-binding molecule
on human platelets, was implicated in both high- and
moderate-affinity pathways of platelet activation (Greco and
Jamieson, 1991). In our study, thrombin-enhanced adhesion
was not significantly affected by pretreatment of SW-480 cells
with AP, (25 jug ml-'), the MAb of GP lb (data not shown),
indicating that the enhanced adhesion did not result from the
binding of thrombin to GP lb on tumour cells. The other
candidate is a high-affinity functional thrombin receptor, a
member of the superfamily of seven-pass transmembrane
proteins (Vu et al., 1991). mRNA encoding this receptor was
detected in human platelets and ECs. Thrombin cleaves this
receptor's amino-terminal extension to create a new receptor
amino terminus that functions as a tethered ligand and
activates the receptor (Vu et al., 1991). Recently Wojtukie-
wicz et al. (1995) reported that thrombin effect is mediated
through the 'tethered ligand' thrombin receptor expressed on
human colon adenocarcinoma (clone A) as well as rat and
mouse solid tumours, thereby promoting tumour cell
adhesion to FN. Thus, we propose that the enhanced
adhesive and migratory effects of thrombin on SW-480
human colon adenocarcinoma cells probably operate in a
similar manner via binding to the 'tethered ligand' thrombin
receptor on SW-480 cells. However, the exact entities that are
responsible for thrombin-enhanced P3 integrin expression
need further investigation.
Our study on thrombin-enhanced SW-480 tumour cell
adhesion to both ECs and FN revealed a bell-shaped dose-
response curve. No stimulatory effect was observed when
tumour cells were incubated with higher doses (i.e. 5 U ml-')
of thrombin. At present, a precise interpretation of this dose
dependency of the thrombin effect is unknown. One
possibility is that thrombin-elicited effects on adhesion
(probably through binding to its high-affinity receptors on
tumour cells) are down-regulated (or desensitised) at high
doses of agonist, a phenomenon that is characteristic of most
G-protein-linked reactions (Greco and Jamieson, 1991;
Wojtukiewicz et al., 1993; Manning and Brass, 1991). An
intact active site serine residue of thrombin molecule was a
prerequisite for its effect on tumour cell adhesion at full
potential since pretreatment of thrombin with hirudin or 3,4-
DCI demonstrated a lower potency than the native form of
the enzyme.
Adhesion of tumour cells to endothelium as well as ECM
are partly mediated by the /3 integrins (i.e. aIIbfl3 and avx/3)
expressed by these cells. Our laboratory previously reported
that phorbol ester and a lipoxygenase metabolite of
arachidonic acid (i.e. 12-(S)-HETE) specifically up-regulate
SW-480 cell-surface expression of aIIb/33 receptors (Chiang et
al., 1994b). In this study, we showed that thrombin
challenged SW-480 cells, resulting in an increased fluores-
cence intensity of immunoreactive /3 integrin probed by using
MAb 7E3, which appears to recognise an antigenic
determinant on the /3 subunit of GpIIb/IIIa (i.e. GpIIIa)
(Chopra et al., 1988). However, 10E5, an MAb that does not
cross-react with the integrins avf3 and a5fl, (Grossi et al.,
1988), markedly blocked the thrombin-enhanced adhesion to
ECs and FN. When compared with the inhibitory potency of
7E3, these results indicate that enhanced adhesion ought to
involve mainly aIbj3 rather than av/33. On the other hand, the
role of Cav#3 in the up-regulation ought not to be excluded as
SW-480 cells showed enhanced migratory activity towards
chemoattractant VN, the primary ligand for 0v03. Similarly,
the enhanced migration was also mediated by a11b/33, the
predominant matrix receptor of platelets that mediates the
binding of FN (Ruoslahti, 1991). This thrombin-enhanced
surface expression of #3 integrins did not require transcrip-
tional regulation and de novo protein synthesis as it was not
affected by actinomycin D and cycloheximide, which is
consistent with the results from Nierodzik et al. (1992). In
our previous study (Chiang et al., 1994b), SW-480 cells
possess an intracellular pool ofintegrin receptors, from which
integrins translocate to the cell surface following PKC
activation. Thus we propose that thrombin might also
promote translocation of /3 integrins from the intracellular
pool to the plasma membrane, which may aid in adhesive
and migratory properties of SW-480 cells. However, we do
not exclude the additional possibility of affinity regulation of
/3 integrins by thrombin, since PKC activation has already
been reported to cause an increase in the fibrinogen-binding
affinity of aIIb/33 in platelets (the 'inside-out' signalling)
(O'Toole et al., 1991; Du et al., 1993). Such intracellular
events may influence the conformation and binding affinity of
the extracellular domain of integrins, thereby altering the
strength and ligand preferences of cell adhesion (Ginsberg et
al., 1992; Brown 1988).
The mechanism whereby PKC activation translates into
adhesive protein up-regulation and increased tumour cell
adhesion remains to be elucidated. PKC represents a family
of serine/threonine protein kinases that provide regulatory
functions in intracellular signal transduction and are
implicated in tumour growth, promotion and differentiation
as well as oncogene activation and carcinogenesis (Liu et al.,
1992). Several observations (Grossi et al., 1989; Chopra et al.,
1991) have indicated that 12(S)-HETE works via PKC
activation to promote tumour cell adhesion to ECs.
Likewise, PKC has been suggested to be involved in
mediating the cellular effects of thrombin (Gomez et al.,
1988; di Corleto and de la Motte, 1989). Therefore, we used
the non-selective but potent protein kinase inhibitor,
staurosporine, and the selective inhibitor of PKC, calphostin
C, to examine the effect of thrombin. Calphostin C markedly
prevented thrombin-enhanced adhesion, which is similar to
the effect of staurosporine. This indicates that thrombin-
elicited effects probably operate via PKC activation.
In our study, thrombin challenge of human colon
adenocarcinoma cells up-regulates cell-surface expression of
/3 integrins, which promote the migration and adhesion of
tumour cells to FN and ECs. Because the interactions of
tumour cells with platelets and plasma components generate
thrombin and some lipoxygenase metabolite of arachidonic
acid (i.e. the thrombin-dependent TCIPA owing to tissue
factor activity expression on SW-480 cells), which may
potentiate metastatic ability, our serial studies implied that
if a significant number ofcolon adenocarcinoma cells induced
TCIPA followed by thrombin-enhanced metastasis process,
PKC inhibitors as well as integrin receptor antagonists
(particularly the potent Arg-Gly-Asp-containing venom
peptide, rhodostomin) might be considered as possible
adjuvant therapeutic agents in the prevention of certain
cancer metastasis. Further studies are being undertaken to
explore the antimetastatic effect of rhodostomin on the
metastasis of SW-480 cells in experimental animals.
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